胰激肽原酶肠溶片联合贝那普利治疗糖尿病肾病70例

Pancreatic Kallidinogenase Enteric- Coated Tablets Combined with Benazepril for Treating Diabetic Nephropathy in 70 Cases

目的观察胰激肽原酶肠溶片联合贝那普利治疗糖尿病肾病的疗效。方法选取140例糖尿病肾病患者随机分为血管紧张素转换酶抑制剂(ACEI)组和联合用药组,各70例。ACEI组单独使用贝那普利,联合用药组在使用贝那普利的基础上联合使用胰激肽原酶肠溶片,观察两组患者治疗前后尿白蛋白排出量(UAER)、血尿素氮(BUN)、血肌酐(SCr)。结果两组治疗后24 h尿蛋白定量下降大于0.5 g/24 h,UAER下降大于38.77μg/min,都较治疗前有显著改善(P<0.05)。联合用药组疗效明显优于ACEI组(P<0.05)。结论胰激肽原酶肠溶片联合贝那普利治疗糖尿病肾病比单独使用贝那普利疗效更好,且胰激肽原酶片还可改善糖尿病患者的肾功能,值得进一步研究和推广。

Objective To observe and compare the effects of Pancreatic Kallidinogenase Enteric-Coated Tablets combined with benazepril in treating diabetic nephropathy. Methods 140 patients with diabetic nephropathy were selected and randomly divided into the combined medication group and the combined medication group, 70 cases in each group. The ACEI group used benazepri alone, while the combined medication group used Pancreatic Kallidinogenase Enteric- Coated Tablets combined with benazepfil. The indexes of urinary albumin excretion rate （UAER）, blood urea nitrogen （BUN） and blood creatinine （SCR） before and after treatment were ob- served in the two groups. Results The 24 h urinary protein quantity after treatment in the two group was decreased by 0.5 g/24 h and more and UAER was decreased by 38.77 μg/min and more, which were significantly improved compared with before treatment（P〈 0. 05）, but the combined medication group was significantly superior to the ACEI group（ P 〈 0.05）. Conclusion Pancreatic Kallidino- genase Enteric- Coated Tablets combined with benazepril is better than single benazepri for treating diabetic nephropathy. Pancreatic Kallidinogenase Tablets can improve the renal function, has the clinical application value and deserves to be further researched and pro- moted.